Cargando…
Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort
Cytokine autoantibodies, particularly those directed to type I interferon (T1IFN), have been reported to portend an increased risk of severe COVID-19. Since SLE is one of the conditions historically associated with T1IFN autoantibodies, we sought to determine the prevalence of cytokine autoantibodie...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990260/ https://www.ncbi.nlm.nih.gov/pubmed/35393285 http://dx.doi.org/10.1136/lupus-2022-000667 |
_version_ | 1784683341016989696 |
---|---|
author | Choi, May Y Clarke, Ann Elaine Buhler, Katherine Jung, Michelle Mathew, Hannah Zhang, Meifeng Cardwell, Francesca S Waldhauser, Heather Fritzler, Marvin J |
author_facet | Choi, May Y Clarke, Ann Elaine Buhler, Katherine Jung, Michelle Mathew, Hannah Zhang, Meifeng Cardwell, Francesca S Waldhauser, Heather Fritzler, Marvin J |
author_sort | Choi, May Y |
collection | PubMed |
description | Cytokine autoantibodies, particularly those directed to type I interferon (T1IFN), have been reported to portend an increased risk of severe COVID-19. Since SLE is one of the conditions historically associated with T1IFN autoantibodies, we sought to determine the prevalence of cytokine autoantibodies in our local cohort of 173 patients with SLE prepandemic and intrapandemic, of which nine had confirmed exposure to SARS-CoV-2. Autoantibodies to 16 different cytokines, including T1IFN, were measured by an addressable laser bead immunoassay. None of the 9 patients with confirmed exposure to SARS-CoV-2 had autoantibodies to T1IFN and none had severe COVID-19 symptoms, necessitating hospitalisation. Hence, we could not confirm that TIIFN autoantibodies increase the risk for severe COVID-19. In addition, the cytokine autoantibody pattern did not differ between those with and without evidence of SARS-CoV-2 exposure. |
format | Online Article Text |
id | pubmed-8990260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-89902602022-04-11 Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort Choi, May Y Clarke, Ann Elaine Buhler, Katherine Jung, Michelle Mathew, Hannah Zhang, Meifeng Cardwell, Francesca S Waldhauser, Heather Fritzler, Marvin J Lupus Sci Med Brief Communication Cytokine autoantibodies, particularly those directed to type I interferon (T1IFN), have been reported to portend an increased risk of severe COVID-19. Since SLE is one of the conditions historically associated with T1IFN autoantibodies, we sought to determine the prevalence of cytokine autoantibodies in our local cohort of 173 patients with SLE prepandemic and intrapandemic, of which nine had confirmed exposure to SARS-CoV-2. Autoantibodies to 16 different cytokines, including T1IFN, were measured by an addressable laser bead immunoassay. None of the 9 patients with confirmed exposure to SARS-CoV-2 had autoantibodies to T1IFN and none had severe COVID-19 symptoms, necessitating hospitalisation. Hence, we could not confirm that TIIFN autoantibodies increase the risk for severe COVID-19. In addition, the cytokine autoantibody pattern did not differ between those with and without evidence of SARS-CoV-2 exposure. BMJ Publishing Group 2022-04-06 /pmc/articles/PMC8990260/ /pubmed/35393285 http://dx.doi.org/10.1136/lupus-2022-000667 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Brief Communication Choi, May Y Clarke, Ann Elaine Buhler, Katherine Jung, Michelle Mathew, Hannah Zhang, Meifeng Cardwell, Francesca S Waldhauser, Heather Fritzler, Marvin J Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort |
title | Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort |
title_full | Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort |
title_fullStr | Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort |
title_full_unstemmed | Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort |
title_short | Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort |
title_sort | cytokine autoantibodies in sars-cov-2 prepandemic and intrapandemic samples from an sle cohort |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990260/ https://www.ncbi.nlm.nih.gov/pubmed/35393285 http://dx.doi.org/10.1136/lupus-2022-000667 |
work_keys_str_mv | AT choimayy cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort AT clarkeannelaine cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort AT buhlerkatherine cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort AT jungmichelle cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort AT mathewhannah cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort AT zhangmeifeng cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort AT cardwellfrancescas cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort AT waldhauserheather cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort AT fritzlermarvinj cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort |